Androgen-responsive POSLUMA-guided Intra-prostatic Boost
NCT07393867
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Intermediate Risk Prostate Cancer
- High Risk Prostate Cancer
- Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Martin T. King, MD, PhD
- Last updated on ClinicalTrials.gov
- May 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center · Milford, MA
- Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital · Weymouth, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.